NASDAQ: TBIOTelesis Bio Inc Stock
$0.33-0.05 (-13.16%)
Updated Apr 18, 2024
TBIO Price
$0.33
Fair Value Price
N/A
Market Cap
$9.96M
52 Week Low
$0.30
52 Week High
$3.01
P/E
-0.2x
P/B
41.87x
P/S
0.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$27.51M
Earnings
-$47.72M
Gross Margin
61.6%
Operating Margin
-162.11%
Profit Margin
-178.2%
Debt to Equity
171.74
Operating Cash Flow
-$35M
Beta
1.47
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TBIO Overview
Codex DNA, Inc. manufactures and sells synthetic biology instruments, reagents, associated products, and provides related services to pharmaceutical and academic laboratories worldwide. Its solutions and products include BioXp, BioXp portal, BioXp kits, Cloud-based scripts, Benchtop reagents, and Biofoundry Services. Known as SGI-DNA, Inc.until 2020/03, Codex DNA was incorporated in 2011 and is headquartered in San Diego, CA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TBIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TBIO is poor value based on its book value relative to its share price (41.87x), compared to the US Medical Devices industry average (3.63x)
P/B vs Industry Valuation
TBIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TBIO due diligence checks available for Premium users.
Be the first to know about important TBIO news, forecast changes, insider trades & much more!
TBIO News
Valuation
TBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
28.61x
Market
41.33x
TBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
41.87x
Industry
3.63x
TBIO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TBIO's financial health
Profit margin
Revenue
$7.0M
Net Income
-$17.7M
Profit Margin
-261.8%
TBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TBIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$70.4M
Liabilities
$40.9M
Debt to equity
171.74
TBIO's short-term assets ($30.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TBIO's long-term liabilities ($32.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.3M
Investing
$6.5M
Financing
-$15.0M
TBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TBIO vs Medical Device Stocks
Telesis Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.